Autoantibodies to PAD4 and BRAF in rheumatoid arthritis

Autoimmunity Reviews

Volumn 11, Issue 11, 2012, Pages 801-803

  Auger, Isabelle ^a   Charpin, Caroline ^a,b   Balandraud, Nathalie ^a,b   Martin, Marielle ^a   Roudier, Jean ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

Autoantibodies; BRAF; PAD4; Rheumatoid arthritis

Indexed keywords

AUTOANTIBODY; B RAF KINASE ANTIBODY; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN ANTIBODY; PROTEIN ARGININE DEIMINASE ANTIBODY; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANKYLOSING SPONDYLITIS; ANTIBODY DETECTION; ANTIBODY SCREENING; ANTIGEN BINDING; CARBOXY TERMINAL SEQUENCE; CHEMICAL MODIFICATION; CITRULLINATION; CYTOKINE PRODUCTION; DIAGNOSTIC TEST; EPITOPE MAPPING; HUMAN; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; UNFOLDED PROTEIN RESPONSE;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; AUTOANTIGENS; HUMANS; HYDROLASES; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84865353267     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2012.02.009     Document Type: Review

References (27)

1. Symmons D.P.M. What is rheumatoid arthritis?. Br Med Bull 1995, 55:243-248.
2. Schellekens G.A., de Jong B.A., van den Hoogen F.H., van de Putte L.B., van Venrooij W.J. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998, 101:273-281.
3. van Venrooij W.J., Pruijn G.J. Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res 2000, 2:249-251.
4. Suzuki A., Yamada R., Yamamoto K. Citrullination by peptidylarginine deiminase in rheumatoid arthritis. Ann N Y Acad Sci 2007, 1108:323-339.
5. Suzuki A., Yamada R., Chang X., Tokuhiro S., Sawada T., Suzuki M., et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4 are associated with rheumatoid arthritis. Nat Genet 2003, 4:395-402.
6. Iwamoto T., Ikari K., Nakamura T., Kuwahara M., Toyama Y., Tomatsu T., et al. Association between PADI4 and rheumatoid arthritis: a meta-analysis. Rheumatology 2006, 45:804-807.
7. Harney S.M., Meisel C., Sims A.M., Woon P.Y., Wordsworth B.P., Brown M.A. Genetic and genomic studies of PADI4 in rheumatoid arthritis. Rheumatology 2005, 7:869-872.
8. Cantaert T., Coucke P., De Rycke L., Veys E.M., De Keyser F., Baeten D. Functional haplotypes of PADI4: relevance for rheumatoid arthritis specific synovial intracellular citrullinated proteins and anti citrullinated protein antibodies. Ann Rheum Dis 2005, 64:1316-1320.
9. Simon M., Girbal E., Sebbag M., Gomès-Daudrix V., Vincent C., Salama G. The cytokeratin filament aggregating protein filaggrin is the target of the so called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis. J Clin Invest 1993, 92:1387-1393.
10. Girbal-Neuhauser E., Durieux J.J., Arnaud M., Dalbon P., Sebbag M., Vincent C., et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 1999, 162:585-594.
11. Vossenaar E.R., Després N., Lapointe E., van der Heijden A., Lora M., Senshu T., et al. Rheumatoid arthritis-specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004, 6:R142-R150.
12. Masson-Bessiere C., Sebbag M., Girbal-Neuhauser E., Nogueira L., Vincent C., Senshu T., et al. The major synovial target of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the a and b chains of fibrin. J Immunol 2001, 166:4177-4184.
13. Auger I., Balandraud N., Rak J., Lambert N., Martin M., Roudier J. New autoantigens in rheumatoid arthritis: screening 8268 protein arrays with RA patients' sera. Ann Rheum Dis 2009, 68:591-594.
14. Takizawa Y., Sawada T., Suzuki A., Yamada R., Inoue T., Yamamoto K. Peptidylarginine deiminase 4 (PADI4) identified as a conformation-dependent autoantigen in rheumatoid arthritis. Scand J Rheumatol 2005, 3:212-215.
15. Roth E.B., Stenberg P., Book C., Sjöberg K. Antibodies against transglutaminases, peptidylarginine deiminase and citrulline in rheumatoid arthritis: new pathways to epitope spreading. Clin Exp Rheumatol 2006, 1:12-18.
16. Halvorsen E.H., Pollmann S., Gilboe I.M., van der Heijde D., Landewé R., Ødegård S., et al. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. Ann Rheum Dis 2008, 67:414-417.
17. Zhao J., Zhao Y., He J., Jia R., Li Z. Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis. J Rheumatol 2008, 35:969-974.
18. Harris M.L., Darrah E., Lam G.K., Bartlett S.J., Giles J.T., Grant A.V., et al. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum 2008, 58:1958-1967.
19. Anzilotti C., Pratesi F., Tommasi C., Migliorini P. Peptidylarginine deiminase 4 and citrullination in health and disease. Autoimmun Rev 2010, 9:158-160.
20. Roberts T.M. Cell biology: a signal chain of events. Nature 1992, 360:534-535.
21. Crews C.M., Erikson R.L. Extracellular signals and reversible protein phosphorylation: what to Mek of it all. Cell 1993, 74:215-217.
22. Thalhamer T., McGrath M.A., Harnett M.M. MAPKs and their relevance to arthritis and inflammation. Rheumatology 2008, 47:409-414.
23. Reuter C.W., Catling A.D., Jelinek T., Weber M.J. Biochemical analysis of MEK activation in NIH3T3 fibroblasts. Identification of B-Raf and other activators. J Biol Chem 1995, 270:7644-7655.
24. Andersen M.H. Immunogenicity of constitutively active V599E Braf. Cancer Res 2004, 64:5456-5460.
25. Fensterle J., Becker J.C., Potapenko T., Heimbach V., Vetter C.S., Bröcker E.B., et al. B-Raf specific antibody responses in melanoma patients. BMC Cancer 2004, 124:62-70.
26. Auger I., Martin M., Balandraud N., Roudier J. RA specific autoantibodies to PAD4 inhibit citrullination of fibrinogen. Arthritis Rheum 2010, 62:126-131.
27. Charpin C., Martin M., Balandraud N., Roudier J., Auger I. Autoantibodies to BRAF, a new family of autoantibodies associated with rheumatoid arthritis. Arthritis Res Ther 2010, 12:R194.